Physician profile
Michael E Simons
NPI 1265433015
$7,608.51
in general payments reported to CMS, 2019-2025
25 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $749 · 2021: $1,187 · 2022: $1,265 · 2023: $1,369 · 2024: $1,279 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,742 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,742.31 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $1,684.74 | 2019-2025 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,601.49 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,469.43 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $497.33 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $408.00 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $381.00 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $213.82 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $194.78 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $187.15 | 2020-2023 | |
| Pfizer INC. | $136.51 | 2023-2025 | |
| Redhill Biopharma INC. | $133.86 | 2020-2022 | |
| Intuitive Surgical, INC. | $124.74 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $109.39 | 2022-2023 | Dupixent |
| Qol Medical, LLC | $68.48 | 2021-2024 | Sucraid, Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.44 | 2023-2024 | Cyltezo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $59.71 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $50.01 | 2024 | Tremfya |
| Mylan Institutional INC. | $44.97 | 2023 | Hulio |
| Romark Laboratories, Lc | $43.41 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $38.86 | 2024-2025 | Vowst |
| Valinor Pharma, LLC | $28.47 | 2025 | Movantik |
| Braintree Laboratories, INC. | $22.61 | 2019 | |
| Lucid Diagnostics INC. | $20.46 | 2023 | |
| Shionogi INC | $11.88 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.